GlassScriptPhysician profile
Michelle Shippert
NPI 1558546747
$9,174.67
in general payments reported to CMS, 2019-2025
32 companies · $1,834 in 2025
The $1,834 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $355 · 2021: $799 · 2022: $1,532 · 2023: $1,873 · 2024: $2,082 · 2025: $1,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,778 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,777.55 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,310.75 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $985.55 | 2020-2025 | Caplyta |
| Alkermes, INC. | $907.05 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $819.24 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $683.32 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $649.99 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $637.37 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $574.89 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $443.90 | 2021-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $382.57 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $329.46 | 2023-2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $272.18 | 2019-2025 | Zepbound, Mounjaro |
| Indivior INC. | $161.38 | 2019-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $160.39 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $148.22 | 2025 | Cobenfy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $101.66 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $81.71 | 2022-2023 | Fanapt, Hetlioz |
| Shire North American Group INC | $79.48 | 2019 | |
| Allergan, INC. | $72.15 | 2019-2020 | |
| Corium, LLC | $69.88 | 2023-2024 | Azstarys |
| Jazz Pharmaceuticals INC. | $56.14 | 2021 | |
| Merck Sharp & Dohme LLC | $44.05 | 2022-2023 | Belsomra |
| Eisai INC. | $35.74 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $28.31 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.98 | 2025 | Rejoyn |
| Noven Therapeutics, LLC | $22.52 | 2024 | Xelstrym, Secuado |
| Supernus Pharmaceuticals, INC. | $21.59 | 2019 | |
| Collegium Pharmaceutical, INC. | $18.12 | 2025 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $15.76 | 2022 | |
| Neuronetics, INC. | $14.55 | 2019 | |
| Acadia Pharmaceuticals INC | $11.80 | 2020 | |
| Neos Therapeutics, LP | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Shippert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.